What is the story about?
What's Happening?
Tagomics Ltd. has published a study in 'Cell Reports Methods' showcasing its new epigenomic profiling technology, Active-Seq, which is part of its Activace platform. This technology targets unmethylated DNA regions for enrichment, providing a comprehensive view of the epigenome. The study highlights the application of this method in identifying biomarkers and disease profiling in colorectal cancer patients. Active-Seq offers a scalable solution for liquid biopsy samples, enabling the detection of abnormal DNA methylation signals. This approach could improve the detection and characterization of diseases by deconvoluting the tissue of origin of cell-free DNA in blood samples.
Why It's Important?
The introduction of this new epigenomic profiling method is a significant advancement in cancer diagnostics, particularly for liquid biopsy applications. By enabling more accurate and comprehensive biomarker discovery, this technology could enhance early detection and monitoring of cancer, leading to better patient outcomes. The ability to work with low DNA input quantities makes it suitable for a wide range of clinical applications, potentially transforming how cancer is diagnosed and managed. This development could benefit the healthcare industry by providing more effective diagnostic tools, ultimately improving patient care and treatment strategies.
AI Generated Content
Do you find this article useful?
